(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with Multiple Sclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Carrillo-Salinas, FJ; Fernández-Ruiz, J; Franco, R; Gómez-Cañas, M; Goya, P; Guaza, C; Hurst, DP; Jagerovic, N; Lagartera, L; Morales, P; Navarro, G; Pazos, R; Reggio, PH | 1 |
| Arena, C; Bertini, S; Carpi, S; Cervetto, C; Chicca, A; Chicca, S; D'Andrea, F; Di Cesare Mannelli, L; Digiacomo, M; Gado, F; Gertsch, J; Ghelardini, C; Lucarini, E; Macchia, M; Manera, C; Marcoli, M; Nieri, P; Poli, G; Polini, B; Reynoso-Moreno, I; Tuccinardi, T; Vallini, E | 1 |
| Cheng, J; Duan, W; Hua, T; Li, F; Liu, ZJ; Nie, H; Sun, Y; Wang, H; Wu, M; Xu, Y; Yang, L; Zhang, T; Zhang, Z | 1 |
3 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and Multiple Sclerosis
| Article | Year |
|---|---|
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
Topics: Dose-Response Relationship, Drug; HEK293 Cells; Humans; Models, Molecular; Molecular Structure; Multiple Sclerosis; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2016 |
The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Female; Ligands; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Multiple Sclerosis; Protein Binding; Pyridones; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2020 |
Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
Topics: Animals; Cannabinoids; Carbon; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Multiple Sclerosis; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Silicon; Structure-Activity Relationship | 2021 |